You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 8, 2024

Claims for Patent: 10,017,740

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,017,740

Title:	Deriving brown adipose tissue cells
Abstract:	The present invention relates to brown adipose tissue (BAT) cells derived from adult stern or progenitor cells, derived from adult white fat tissue (WAT), as well as to methods for deriving such cells.
Inventor(s):	Tarunina; Marina (Stevenage, GB), Choo; Yen (Stevenage, GB), Jeyakumar; Mylvaganam (Stevenage, GB), Watson; Thomas (Stevenage, GB), Rosell; Meritxell (Stevenage, GB), Hook; Lilian (Stevenage, GB), Hernandez; Diana (Stevenage, GB)
Assignee:	Plasticell Limited (London, GB)
Application Number:	14/664,441
Patent Claims:	1. A method for deriving a brown adipose tissue (BAT) cell from an adult adipose tissue derived stem cell, comprising culturing the stem cell in mesechymal stem cell growth medium, and transferring the cell to a medium comprising Rosiglitazone, Triidothyronine (T3), Dexamethasone, IBMX and BMP-7. 2. A method according to claim 1, in which the cells are not transfected with transgenes. 3. A method according to claim 1, wherein 20% or more of the adult stem cells are differentiated into BAT cells. 4. A method according to claim 3, wherein 50% or more of the adult stem cells are differentiated into BAT cells. 5. A method according to claim 1, comprising exposing the stem cell to the following media combinations: (i) MSC SFM; (ii) DMEM/F12, insulin, transferrin, BMP-7, T3, Dexamethasone, Rosiglitazone and IBMX; and optionally; (iii) DMEM/F12, insulin, transferrin, BMP-7, T3, Dexamethasone and Rosiglitazone. 6. A method according to claim 5, wherein step (iii) is repeated by refreshing the medium. 7. A method according to claim 1, wherein the cells are exposed to the media sequentially, at three-day intervals. 8. A method according to claim 1, wherein the cells are exposed to the media contemporaneously. 9. A method according to claim 1, comprising exposing the stem cell to the following media combinations: (i) MSC SFM; (ii) DMEM/F12, insulin, transferrin, BMP-7, T3, Dexamethasone, Rosiglitazone and IBMX; and (iii) DMEM/F12, insulin, transferrin, T3, Dexamethasone and Rosiglitazone. 10. A method according to claim 9, wherein steps (ii) and (iii) are repeated by refreshing the medium.

Details for Patent 10,017,740

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biosolutions Canada Inc.	BAT	botulism antitoxin heptavalent (a, b, c, d, e, f, g) - (equine)	Solution	125462	03/22/2013	⤷ Try a Trial	2032-09-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.